• René Kamgang - Institute of Medical Research and Medicinal Plants Studies (IMPM) - Laboratory of Endocrinology and Radioisotopes - Yaounde - General Endocrinology and Metabolism systems (GEMS), Laboratory of Animal Physiology, University of Yaoundé I,
  • Angèle Foyet Fondjo General Endocrinology and Metabolism systems (GEMS), Laboratory of Animal Physiology, University of Yaoundé I,
  • Jean-louis Essame Oyono - Laboratory of Endocrinology and Radioisotopes, Institute of Medical Research and Medicinal plants Studies (IMPM), Yaoundé, Cameroon; - Faculty of Medicine and Biomedical Sciences, University of Yaoundé I


Objectives: The effect of methanolic extract of Kalanchoe crenata (MEKC) was investigated on renal morphology and function in adriamycin-induced kidney impairment in rats.

Methods: Ether anesthetized rats received three intravenous injections (days 0, 14, 28) of 2 mg/kg body weight of adriamycin. Repeated doses of the extract (0, 50 and 68 mg/kg bw) and losartan (10 mg/kg bw) were administered orally once daily, for 6 weeks, to adriamycin- nephropathic rats. Kidney functions were assessed through proteinuria, creatinemia and creatinuria, renal malondialdehyde (MDA) level, superoxide dismutase (SOD) activity and morphology analyses.

Results: The 50 and 68 mg/kg MEKC, as the losartan, decreased proteinuria: -63.74 % and -64.94 % respectively, significantly (P<0.01) increased the creatinuria and the creatinuria/creatinemia ratio, and also decreased the creatinemia in diseased rats. The plant extracts markedly (P<0.05) increased plasma sodium, and decreased (P<0.01) the urinary sodium and potassium levels. The MEKC has remarkably (P<0.01) decreased the level of the thiobarbituric acid reactive substances and increased the SOD level in nephropathic rats. The extract has improved the damage of kidney induced by adriamycin.

Conclusion: The results indicate that the treatment with the K. crenata methanolic extract may improve proteinuria and all the symptoms that breed from nephropathy, and could improve kidney morphology. Therefore, K. crenata could be promising for the development of a standardized phytomedicine for the treatment of kidney disease.


Keywords: Adriamycin, Kalanchoe crenata, Nephropathy, Antioxidant, Rat, Methanol extract


Download data is not yet available.


1. Fogo AB, Kon V. Pathophysiology of progressive renal diseases-An overview In: Immunologic Renal Diseases; 2 ed, edited by Neilson EG, Couser WG Philadelphia, Lippincott Williams and Wilkins; 2001. p. 55-72.
2. Lee VWS, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrol 2011;16(1):30–8.
3. Andrade LGM, Viero RM, Carvalho MFC. Treatment of Adriamycin-induced nephropathy with erythropoietin and G-CSF. J Nephrol 2013;26(3):534-9.
4. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382(9888):260-72.
5. Schnaper HW. Focal segmental glomerulosclerosis. In: Immunologic Renal Diseases; 2 ed, edited by Neilson EG, Couser WG philadelphia, Lippincott Williams and Wilkins; 2004. p. 1001-27.
6. WHO. Launches of the first global strategy on the traditional medicine. WHO Press Release 2002;38:2.
7. Dimo T, Fotio LA, Nguelefack TB, Asongalem EA, Kamtchouing P. Anti-inflammatory activity of leaf extracts of Kalanchoe Crenata Andr. Indian J Pharmacol 2006;28:115-9.
8. Kamgang R, Youmbi Mboumi R, Foyet Fondjo A, Fokam Tagne AM, Mengue Ndillé PR, Ngogang Yonkeu J. Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (crassulaceae). J Nat Med 2008;62:34-40.
9. Stoyanoff TR, Todaro JS, Aguirre MV, Brandan NC. Cell stress, hypoxic response and apoptosis in murine Adriamycin-induced nephropathy. J Pharmacol Toxicol 2012;7(8):344-58.
10. Zhao M, Li M, Li X, Shao C, Yin J, Gao Y. Dynamic changes of urinary proteins in a focal segmental glomerulosclerosis rat model. Proteome Sci 2014;12:42.
11. Ho-jung, jun-hoRtu, Sang-woong Han IIe, Kyu Park, Seung Sam Paik, Moon HyangParkm Doo Jin Paik, et al. Combined therapy of Cilazapril and Losartan has no additive effects in ameliorating Adriamycin-induced glomerulopathy. Nephron Physiol 2004;97:58-65.
12. Sofowora A. Medicinal Plants and Traditional Medicine in Africa. 2nded: Spectrum Books Ltd; Ibadan, Nigeria; 1993. p. 1-153.
13. Molle J. Limite de tolérance et toxicité de quelques aminosides (Forme L et DL). Aminopeptides-proteine. Cahier n°4, Ed AEC Paris; 1986. p. 207-32.
14. Smith JA, Van den Broek FAR, Canto´Martorell J, Hackbarth H, Ruksenas O, Zeller W. Principles and practice in ethical review of animal experiments across Europe: summary of the report of a Federation of European Laboratory Animal Science Associations (FELASA) working group on ethical evaluation of animal experiments. Lab Anim 2007;41:143–60.
15. Wang Y, Wang YP, Tay YC, Harris DCH. Progressive Adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000;58:1797-804.
16. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
17. Flohe L, Otting F. Superoxide dismutase assays. Methods Enzymol 1984;105:93-104.
18. Viau C, Tardif R. Toxicologie. In: Environnement et Santé publique-Fondements et pratiques. Gérin M, Gosselin P, Cordier S, Viau C, Quénel P, Dewailly E, rédacteurs. Edisem/Tec & Doc, Acton Vale/Vale; 2003. p. 119-43.
19. Kriy W, Lettir M. Pathways to nephron loss starting from glomerular diseases in sights from animal models. Kidney Int 2005;67:404-19.
20. Koshikawa Masao, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephritic syndrome. J Am Soc Nephrol 2005;16:2690–701.
21. Yang W, Wang J, Shi L, Yu L, Qian Y, Liu Y, et al. Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in Adriamycin-induced nephropathy in rats. Cytokine 2012;59(2):370-6.
22. Chen Z, Zhu L, Zhen Y, Li D, Tang B, Chen W, et al. Anti-proteinuric effect of sulodexide in Adriamycin-induced nephropathy rats. Lat Am J Pharm 2012;31(7):963-7.
23. Mihailovic-Stanojevic N, Jovovic D, Miloradovic Z, Grujic-Milanovic J, Jerkic M, Markovic-Lipkovski M. Reduced progression of Adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrol Dial Transplant 2009;24:1142-50.
24. Vavrinec P, Dokkum RPE, Goris M, Buikema H, and Henning RH. Losartan protects mesenteri arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy. J Renin-Angiotensin-Aldosterone Syst 2011;12(3):184-94.
25. Harris RC, Neilson EG. Toward a unified theory of renal progression. Ann Rev Med 2006;57:365-80.
26. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year: a histological book to the future. Ann N Y Acad Sci 2000;899:136-47.
27. Usui HK, Shikata K, Saski M, Okada S, Matsuda M, Shikta Y, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy though amelioration of microinflammation. Diabetes 2007;56:363-72.
28. Abbate M, Zoja C, Cornad. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular inflammation. J Am Soc Nephrol 1998;9:1213-3.
29. Montilla MP, AgilA, Navarro MC. Antioxidant activity of Maslinic acid, a Triterpene Derivative obtained from oleaeuropaea. Planta Med 2003;69:472-4.
183 Views | 843 Downloads
How to Cite
Kamgang, R., A. F. Fondjo, and J.- louis E. Oyono. “EFFECT OF METHANOLIC FRACTION OF KALANCHOE CRENATA ON RENAL MORPHOPHYSIOLOGY IN ADRIAMYCIN-INDUCED IMPAIRED KIDNEY IN RATS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 2, Dec. 2014, pp. 89-93, https://innovareacademics.in/journals/index.php/ijpps/article/view/3675.
Original Article(s)